Claims for Patent: 9,833,512

Summary for Patent: 9,833,512

Title:	Blocking IL-9 signaling in conjunction with chemotherapy to treat cancer
Abstract:	This document provides methods and materials related to using inhibitors of IL-9 signaling in conjunction with chemotherapy to treat cancer (e.g., solid tumors). For example, methods and materials for using inhibitors of IL-9 signaling (e.g., anti-IL9 antibody preparations) in conjunction with chemotherapy to treat cancer (e.g., solid tumors such as breast cancer tumors or colon cancer tumors) or to reduce the growth rate of cancer (e.g., solid tumors such as breast cancer tumors or colon cancer tumors) within a mammal are provided.
Inventor(s):	Hoelzinger; Dominique B. (Phoenix, AZ), Gendler; Sandra J. (Scottsdale, AZ), Cohen; Peter A. (Scottsdale, AZ), Dominguez; Ana L. (Scottsdale, AZ), Smith; Shannon E. (Spring Valley, CA), Lustgarten; Joseph (Scottsdale, AZ)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	14/682,493
Patent Claims:	1. A method for treating a mammal having colon or breast cancer, wherein said method comprises administering, to said mammal, a therapeutically effective amount of an agent and an inhibitor of IL-9 signaling, wherein said agent is selected from the group consisting of an anti-PD-1 agent, an anti-PD-L1 agent, an anti-CTLA4 agent, trastuzumab, cyclophosphamide, gemcitabine, capecitabine, azacytadine, bortezomib, carboplatin, cisplatin, etoposide, imatinib, 5-fluorouracil, docetaxel, paclitaxel, nab-paclitaxel, irinotecan, doxorubicin, methotrexate, and oxaliplatin, wherein said inhibitor comprises an anti-IL-9 or anti-IL-9 receptor antibody, and wherein the progression of said colon or breast cancer or the number of colon or breast cancer cells within said mammal is reduced. 2. The method of claim 1, wherein said mammal is a human. 3. The method of claim 1, wherein said method comprises administering said agent to said mammal before said inhibitor is administered to said mammal. 4. The method of claim 1, wherein said method comprises administering said agent to said mammal at least one month before said inhibitor is administered to said mammal. 5. The method of claim 1, wherein said method comprises administering said agent to said mammal at least two months before said inhibitor is administered to said mammal.

Details for Patent 9,833,512

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2034-04-09
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2034-04-09
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2034-04-09